Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genomic Analysis Platform Offers Insights into Health, Disease

By Labmedica staff writers
Posted on 14 May 2008
An ultra-high throughput genomic analysis system using new technology for DNA sequencing and genomic analysis has enabled scientists to adopt new approaches for studying the genetic basis of health and disease.

The new platform, the SOLiD system is an end-to-end genomic analysis solution utilizing a proprietary technology called stepwise ligation, which generates high quality data for applications including whole genome sequencing, chromatin immunoprecipitation (ChIP), microbial sequencing, digital karyotyping, medical sequencing, genotyping, gene expression, and small RNA discovery.

Applied Biosystems (Warrington, UK) has developed significant new enhancements to the SOLiD system platform, including upgrades to software and chemistry that double throughput, simplify workflows, and decrease system run times.

With the new upgrades, the SOLiD system can consistently generate more than six billion bases of sequence data per run, maintaining the system as the highest throughput genomic analysis system available today. More...
It can also generate up to 240 million sequence tags per run, which is expected to reduce the cost of conducting sequencing-based gene expression applications further.

Scientists at the Broad Institute of the Massachusetts Institute of Technology (MIT) and Harvard (Cambridge, MA, USA) are using two SOLiD systems for large-scale discovery of genetic variation in human genome samples, as part of the Broad Institute's contribution to the 1000 Genomes Project, a worldwide effort to create the most detailed and medically useful picture of human genetic variation to date. The scientists generated more than 50 billion bases of DNA sequence over just six weeks.

At Columbia University Medical Center (CUMC; New York, NY, USA), scientists have been using the SOLiD system for a novel approach to study whole-genome methylation profiles in a panel of breast cancer tumors, benefiting from the mate-pair analysis capabilities of the system to map the methylation state of all regions of the genome.

The institutes presented their preliminary findings at the Cold Spring Harbor Laboratory's Biology of Genomes meeting in New York (USA) from May 6-10, 2008.


Related Links:
Applied Biosystems
Broad Institute of MIT and Harvard
Columbia University Medical Center

New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Rapid Molecular Testing Device
FlashDetect Flash10
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.